Welcome to our dedicated page for Altria Group news (Ticker: MO), a resource for investors and traders seeking the latest updates and insights on Altria Group stock.
Altria Group, Inc. (MO) provides a centralized hub for tracking corporate developments in tobacco production and strategic investments. This page aggregates official press releases, regulatory filings, and market analysis related to Altria’s operations across cigarettes, smokeless products, and emerging categories.
Investors and industry observers will find timely updates on earnings announcements, manufacturing innovations, and legislative developments affecting the tobacco sector. The curated collection includes filings related to Altria’s subsidiaries like Philip Morris USA and its ventures in heated tobacco technologies.
Key categories include quarterly financial results, partnership announcements, product research milestones, and compliance updates. Content is maintained to reflect Altria’s evolving business strategy while adhering to financial disclosure standards.
Bookmark this page for efficient access to primary source materials about MO’s market activities. Cross-reference updates with SEC filings and official company communications for complete due diligence.
Altria Group, Inc. (NYSE: MO) will host a live audio webcast on April 27, 2023, at 9:00 a.m. ET to discuss its 2023 first-quarter business results. A press release with the results will be available at approximately 7:00 a.m. ET on the same day. The webcast will feature CEO Billy Gifford and CFO Sal Mancuso discussing the results and addressing questions from investors and media. The event requires pre-event registration, and an archived version will be accessible on altria.com following the live session.
Altria Group hosted an investor day conference in New York, detailing its 2028 Enterprise Goals for financial metrics and smoke-free product growth. Key aims include achieving mid-single digit growth in adjusted diluted EPS by 2028 and doubling smoke-free net revenues to $5 billion by growing volumes by at least 35% from 2022 levels. The company reaffirmed its 2023 full-year adjusted diluted EPS guidance of $4.98 to $5.13, reflecting 3% to 6% growth from 2022. Altria's internal product development updates included new smoke-free innovations like SWIC and on! PLUS, with regulatory applications yet to be filed.
Altria Group will host a live webcast of its Investor Day on March 23, 2023, in New York, NY. The event will start at 9:00 a.m. and conclude around 12:30 p.m. Eastern Time. Presentations will be led by Billy Gifford, Altria's CEO, alongside key leadership members. This webcast is available in listen-only mode, and registration is required in advance. Interested participants can find registration details at www.altria.com/webcasts. An archived version of the presentation will be accessible on Altria's website after the event.
Altria Group, Inc. (NYSE: MO) announced a definitive agreement to acquire NJOY Holdings, Inc., a significant move in the company's strategy to enhance its portfolio in the tobacco industry. The announcement was made via a press release at 7:00 a.m. ET on March 6, 2023, followed by a live webcast at 9:00 a.m. ET to discuss the acquisition details. CEO Billy Gifford will lead the discussion, aimed at addressing investor queries. The webcast can be accessed at altria.com.
Altria Group has announced a definitive agreement to acquire NJOY Holdings for about $2.75 billion in cash. The deal includes up to $500 million in contingent payments based on regulatory approvals of certain NJOY products. NJOY’s e-vapor product, NJOY ACE, is the only pod-based e-vapor product authorized by the FDA. Altria aims to leverage its extensive commercial resources to bolster NJOY's market presence, enhancing its smoke-free product portfolio. This acquisition is poised to be accretive to cash flow within two years and improve adjusted diluted EPS within three years.
Altria Group, Inc. (NYSE:MO) has exchanged its minority investment in JUUL Labs, Inc. for a non-exclusive global license to JUUL's heated tobacco intellectual property. This decision comes amid JUUL's ongoing regulatory challenges. CEO Billy Gifford stated this strategy aligns with their business objectives. As of December 31, 2022, the carrying value of Altria's JUUL investment was $250 million, which will be recorded in Q1 2023 as a special item in earnings. The transaction reflects Altria's focus on the e-vapor market and its commitment to lead a smoke-free future.
Altria Group, Inc. (NYSE: MO) has declared a quarterly dividend of
Altria Group, Inc. (NYSE: MO) reported a strong financial performance for Q4 2022 and the full year, with adjusted diluted EPS growth of 5%. Highlights include net revenues of $6.1 billion in Q4, down 2.3% year-over-year, and full-year revenues of $25.1 billion, a 3.5% decline. The company expects 2023 adjusted diluted EPS between $4.98 and $5.13, indicating growth of 3% to 6%. Share repurchases totaled $1.8 billion for 2022, with a new $1 billion program authorized. The firm maintained a dividend payout of $6.6 billion for 2022. Despite some market challenges, brand loyalty and strategic investments position Altria for future growth.
Altria Group (NYSE: MO) will host a live audio webcast on February 1, 2023, at 9:00 a.m. Eastern Time, to discuss its 2022 fourth-quarter and full-year business results. A press release detailing these results will be issued at approximately 7:00 a.m. Eastern Time the same day. CEO Billy Gifford and CFO Sal Mancuso will present the findings and answer questions from the media and investors. The webcast is in listen-only mode, and pre-event registration is required. An archived version will be available on altria.com after the event.
Altria (NYSE: MO) will undertake an equity and civil rights assessment following a shareholder proposal from 2022. This initiative aims to enhance transparency and stakeholder alignment while addressing issues related to tobacco harm. The assessment will be led by Altria and overseen by an external advisory board of experts in civil rights and public health. A report detailing the findings is expected within 12 months. Feedback from top shareholders, representing 43% of outstanding shares, has informed the approach to the assessment.